EMA Suspends Leo’s Actinic Keratosis Drug Picato
Also Limits Use Of High-Strength Estradiol Creams
The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.
You may also be interested in...
After a 14-year-old legal dispute, the European Medicines Agency has now repeated its safety review of high-strength estradiol creams for treating vaginal atrophy and says it stands by its original recommendation to place a limit on how long patients should use these products.
Despite the life sciences industry’s call for continued alignment of medicines regulation with the EU from next year and for some sort of co-operation with the European Medicines Agency, it seems the UK government is prepared to make only small concessions.
The UK’s decision to pull out of Europe’s Unified Patent Court system throws the future of the whole project into doubt.